Finnish healthcare company Biohit Oyj has made a decision to share study protocols, i.e., descriptions of clinical studies designed for validation of Biohit Oyj’s diagnostic tests as well as for evaluation of therapeutic efficacy of Biohit’s Acetium capsule and lozenge products in current and novel clinical indications.
CEO Semi Korpela, Biohit Oyj: “While making all research protocols publicly available through Biohit company website, Biohit Oyj has the intention to stimulate interest in these diagnostic tests and therapeutic products all over the world.”
CEO Semi Korpela, Biohit Oyj Tel. +358 9 773 861 email@example.com www.biohithealthcare.com
This news release was distributed by GlobeNewswire, www.globenewswire.com – a NASDAQ OMX company